A Single Center, Open Label, Single Group, Phase 1/2a Clinical Study to Evaluate the Safety and Exploratory Efficacy of Transplantation Therapy Using PSA-NCAM(+) NPC Derived From hESC Line in AIS-A Level of Sub-acute SCI(From 7 to 60 Days)

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 26 Sep 2024

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Neural precursor cell therapy-S Biomedics (Primary)
Indications Spinal cord injuries
Focus Adverse reactions
Acronyms SB-SCI-001
Sponsors S Biomedic

Most Recent Events

06 Sep 2024 Planned End Date changed from 1 Sep 2028 to 1 Sep 2030.
06 Sep 2024 Planned primary completion date changed from 1 Dec 2023 to 1 Oct 2028.
03 May 2022 Planned End Date changed from 1 Sep 2023 to 1 Sep 2028.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight